clinical trial · NCT07913061
A Study Comparing SHR-3167 With Insulin Degludec in Adults With Type 2 Diabetes Currently Treated With Basal Insulin
Jiangsu HengRui Medicine Co., Ltd.·phase3·not yet recruiting·n = 680
Diabetes Mellitus, Type 2SHR-3167insulin degludec
brief summary
The purpose of this study is to evaluate efficacy and safety of once-weekly SHR-3167 and once-daily Insulin Degludec in participants with Type 2 diabetes that has been treated with basal insulin. The study consists of a screening period, a treatment period and a safety follow-up period. The study will last up to 33 weeks.
started
Nov 1, 2026
primary completion
Jan 1, 2028
completion
Feb 1, 2028
last updated
Nov 3, 2026
official title
A Multicenter, Randomized, Open-Label, Parallel-Group, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Degludec in Adults With Type 2 Diabetes Currently Treated With Basal Insulin, With or Without Non-Insulin Antidiabetic Drugs
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol